• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

FDA approves Stelara for treatment of psoriasis

Article

Horsham, Pa. ? The U.S. Food and Drug Administration (FDA) has approved the biologic Stelara (ustekinumab, Centocor Ortho Biotech) for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy, according to a Centocor press release.

Horsham, Pa.

- The U.S. Food and Drug Administration (FDA) has approved the biologic Stelara (ustekinumab, Centocor Ortho Biotech) for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy, according to a Centocor press release.

Stelara is a human monoclonal antibody that targets cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), proteins believed to be associated with the development of psoriasis.

The clinical development program for Stelara included more than 2,200 patients and two pivotal phase 3 trials. In each of the trials, a significantly higher proportion of patients receiving either 45 mg or 90 mg of Stelara achieved at least a 75 percent reduction in psoriasis, measured by the Psoriasis Area and Severity Index (PASI), at week 12 as compared to placebo, according to Centocor.

The drug is administered as a subcutaneous injection given at weeks zero and four, followed by a dosing every 12 weeks.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.